论文部分内容阅读
Poly(ADP-ribose) polymerase-1(PARP-1) inhibitors and histone deacetylase(HDAC) inhibitors have recently emerged as promising anticancer drugs. The aim of this study was to investigate the effect of combination treatment with the PARP inhibitor PJ34 and HDAC inhibitor SAHA on the proliferation of liver cancer cells. Cell proliferation and apoptosis were assessed in three human liver cancer cell lines(Hep G2, Hep3 B and HCC-LM3) treated with PJ34(8 μmol/L) and SAHA(1 μmol/L), alone or combined, by Cell Counting Kit-8 assay and flow cytometry, respectively. The nude mice bearing subcutaneous Hep G2 tumors were administered different groups of drugs(10 mg/kg PJ34, 25 mg/kg SAHA, 10 mg/kg PJ34+25 mg/kg SAHA), and the inhibition rates of tumor growth were compared between groups. The results showed that combined use of PJ34 and SAHA could synergistically inhibit the proliferation of liver cancer cell lines Hep G2, Hep3 B and HCC-LM3. The apoptosis rate of Hep G2 cells treated with PJ34+SAHA was significantly higher than that of Hep G2 cells treated with PJ34 or SAHA alone(P<0.05). In vivo, the tumor inhibition rates were 53.5%, 61.4% and 82.6% in PJ34, SAHA and PJ34+SAHA groups, respectively. The combined use of PJ34 and SAHA could significantly inhibit the xenograft tumor growth when compared with use of PJ34 or SAHA alone(P<0.05). It was led to conclude that PJ34 and SAHA can synergistically suppress the proliferation of liver cancer cells.
Poly (ADP-ribose) polymerase-1 (PARP-1) inhibitors and histone deacetylase (HDAC) inhibitors have recently emerged as promising anticancer drugs. The aim of this study was to investigate the effect of combination treatment with the PARP inhibitor PJ34 and HDAC inhibitor SAHA on the proliferation of liver cancer cells. Cell proliferation and apoptosis were assessed in three human liver cancer cell lines (Hep G2, Hep3 B and HCC-LM3) treated with PJ34 (8 μmol / L) and SAHA (1 μmol / L ), alone or combined, by Cell Counting Kit-8 assay and flow cytometry, respectively. The nude mice bearing subcutaneous Hep G2 tumors were administered different groups of drugs (10 mg / kg PJ34, 25 mg / kg SAHA, 10 mg / kg PJ34 + 25 mg / kg SAHA), and the inhibition rates of tumor growth were compared between groups. The results showed that combined growth of PJ34 and SAHA could synergistically inhibit the proliferation of liver cancer cell lines Hep G2, Hep3 B and HCC-LM3 The apoptosis rate of Hep G2 cells treated with PJ34 + SAH In vivo, the tumor inhibition rates were 53.5%, 61.4% and 82.6% in PJ34, SAHA and PJ34 + SAHA groups, respectively. The combined use of PJ34 and SAHA could significantly inhibit the xenograft tumor growth when compared with PJ34 or SAHA alone (P <0.05). It was led to conclude that PJ34 and SAHA can synergistically suppress the proliferation of liver cancer cells.